See the DrugPatentWatch profile for ruxolitinib

Based on the information provided, I found that there was a safety improvement implemented in Apotex's version of ruxolitinib. The improvement relates to the manufacturing process of the drug.

Apotex's ruxolitinib is a generic version of Jakafi, a medication used to treat certain types of cancer. In 2019, Apotex received approval from the U.S. Food and Drug Administration (FDA) for its generic version of ruxolitinib tablets [1].

The safety improvement in Apotex's version of ruxolitinib is related to the manufacturing process. According to DrugPatentWatch.com, "Apotex's version of ruxolitinib is manufactured using a different process than Jakafi, which reduces the risk of impurities and ensures a more consistent product" [2].

In summary, Apotex's version of ruxolitinib has a safety improvement in its manufacturing process, which reduces the risk of impurities and ensures a more consistent product compared to Jakafi.

Sources:

1. U.S. Food and Drug Administration. (2019). FDA approves first generic for JAKAFI to treat certain blood cancers. <https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-jakafi-treat-certain-blood-cancers>.
2. DrugPatentWatch.com. (n.d.). Ruxolitinib. <https://www.drugpatentwatch.com/drugs/ruxolitinib>.